Exhibit (d)(12)
Execution Version
Hildred Perennial Partners I, LP
Hildred Capital Co-Invest-REBA, LP
Hildred Equity Partners III, LP
Hildred Equity Partners III-A
Hildred Equity Partners III-B
January 17, 2025
Crown Laboratories, Inc.
207 Mockingbird Lane
Johnson City, Tennessee 37604
| Re: | Second Amended and Restated Equity Financing Commitment |
Ladies and Gentlemen:
This letter agreement sets forth the amended commitment of Hildred Perennial Partners I, LP, Hildred Capital Co-Invest-REBA, LP, Hildred Equity Partners III, LP, Hildred Equity Partners III-A, LP and Hildred Equity Partners III-B, LP, each a Delaware limited partnership (each of the foregoing, an “Investor” and collectively, the “Investors”), subject to the terms and conditions hereof, to, directly or indirectly, purchase equity or debt securities of Crown Laboratories, Inc., a Delaware corporation (“Parent”), and amends and restates in its entirety the letter agreement, dated as of December 7, 2024, previously entered into by the parties thereto. It is contemplated that pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 by and among Parent, Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Company”) (as amended from time to time, and as amended by that certain Amendment to the Amended and Restated Agreement and Plan of Merger dated as of December 11, 2024, and that certain Amendment No. 2 to the Amended and Restated Agreement and Plan of Merger, dated as of the date hereof, the “Merger Agreement”), Merger Sub shall commence a tender offer to purchase all of the outstanding shares of Company Common Stock, at a price of $3.65 per Share, in cash, without interest (the “Offer”), and following the consummation of the Offer, upon the terms and subject to the conditions set forth in the Merger Agreement, the parties will, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, effect the acquisition of the Company by Parent through the merger of Merger Sub with and into the Company, with the Company continuing as the surviving corporation (the “Merger”) . Capitalized terms used, but not otherwise defined, herein shall have the meanings ascribed to them in the Merger Agreement.
1. | Upon the terms and subject to the conditions set forth herein, each Investor hereby, severally (and not jointly or jointly and severally), commits to purchase (or cause an assignee permitted under this letter agreement to purchase), directly or indirectly, at or immediately prior to the Acceptance Time, its Pro Rata Percentage (as defined in Section 9) of equity or debt securities of Parent for an aggregate purchase price equal to $460,000,000 (the “Commitment”), solely for the purpose of allowing Parent, on the terms and subject to the conditions of the Merger Agreement, to pay the amounts payable by Parent at the Acceptance Time pursuant to Section 2.1(e) and at the Closing pursuant to Section 3.3(a) of the Merger Agreement and to pay fees and expenses required to be paid by Parent or Merger Sub at the Closing under the Merger Agreement, including in connection with the Offer and the Merger (collectively, the “Closing Payments”). Parent agrees to sell, or otherwise issue, such equity or debt securities of Parent (or cause equity or debt securities of a parent company of Parent to be sold or otherwise issued) upon an Investor’s payment of its portion |